bullish
Formycon - Two submissions and two Phase III trials in 2021
SUMMARY
Formycon continues to progress three core biosimilar projects. In H220, it is preparing the FYB201 (Lucentis biosimilar) EMA approval submission and helping in the resubmission of FYB201 to the FDA. FYB203 (Eylea biosimilar) entered Phase III in August. FYB202 (Stelara biosimilar, autoimmunity) is due to enter Phase III imminently. Development income from partners was €16.5m in H120, giving a loss of €1.4m and a cash outflow of €2.1m. Cash was €20.3m on 30 June.
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- Aviva’s £3.7B Acquisition: Key Index Changes
- FnGuide Top10 Index Rebalance Preview: Big Flow in Large Cap Stocks
- Aisin (7259) - Executing the Capital Policy Side of Its MTMP - Big ¥120bn (8.8%) Buyback
- Quiddity JPX-Nikkei 400 Rebal 2025: End Apr 2025 Ranks
- Horizon Robotics (9660 HK): Global Index Inclusion After April & October Lock-Ups
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Edison Investment Research
Leading International Investment Research
Price Chart(Sign Up to Access)
- Formycon - Two submissions and two Phase III trials in 202130 Sep 2020
x